Get the Stockscreener App
60.29
0.72%
0.48
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $60.29, with a volume of 383.44K.
It is up +0.72% in the last 24 hours and up +7.63% over the past month.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$59.81
Open:
$59.99
24h Volume:
383.44K
Relative Volume:
0.04
Market Cap:
$121.37B
Revenue:
$48.30B
Net Income/Loss:
$-8.95B
P/E Ratio:
-13.64
EPS:
-4.42
Net Cash Flow:
$13.94B
1W Performance:
+0.10%
1M Performance:
+7.63%
6M Performance:
+22.61%
1Y Performance:
+14.42%
1-Day Range:
$59.79
$60.39
1-Week Range:
$59.52
$63.33
52-Week Range:
$39.35
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
60.26 | 121.37B | 48.30B | -8.95B | 13.94B | -4.42 |
|
LLY
Lilly Eli Co
|
810.99 | 781.10B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
213.05 | 374.36B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
163.86 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
76.14 | 332.00B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
MRK
Merck Co Inc
|
95.59 | 251.88B | 64.17B | 17.12B | 18.10B | 6.73 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Is Bristol-Myers Squibb Company (BMY) the Best Pharma Stock to Buy According to Hedge Funds? - Insider Monkey
Bristol-Myers Squibb at Leerink Global Healthcare Conference: Pipeline Progress and Strategic Insights - Investing.com India
BMS $286m partner buy secures Abecma and closes chapter on bluebird - BioXconomy
Melanoma Therapeutics Market to Reach $ 8.35 Bn by 2032Key - openPR
11 Best Pharma Stocks to Buy According to Hedge Funds - Insider Monkey
Bristol Myers Squibb (BMY) Shares Cross 4% Yield Mark - Nasdaq
Bristol Myers Squibb Acquires 2seventy bio for $286 Million - Lawyer Monthly Magazine
Bristol-Myers Squibb Company agreed to acquire 2seventy bio, Inc. for approximately $280 million. - Marketscreener.com
Bristol-Myers Squibb Company agreed to acquire 2seventy bio, Inc.. -March 10, 2025 - Marketscreener.com
Eaton's Bold Acquisition Moves Into Data Centers - Finimize
2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M - BioPharma Dive
Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million - Reuters.com
Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal - Benzinga
Bristol Myers Squibb's Bold Move: Acquiring 2seventy Bio - Finimize
Bristol Myers to acquire cell therapy partner 2seventy bio in $286M all-cash deal (BMY:NYSE) - Seeking Alpha
Bristol Myers to acquire cell therapy partner 2seventy bio in $286M all-cash deal - MSN
Bristol Myers to acquire 2seventy bio for $286 million - Investing.com India
Bristol Myers to buy collaborator 2seventy bio for $286 mln By Investing.com - Investing.com South Africa
Bristol Myers to buy collaborator 2seventy bio for $286 mln - Investing.com
Bristol Myers to acquire 2seventy bio for $286 million By Investing.com - Investing.com UK
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb - Business Wire
Bristol Myers Stock Gains 9.2% in a Month: Should You Buy Now or Wait? - Nasdaq
#AAD25: What you need to know from Amgen, Bristol Myers, J&J and more - Endpoints News
Bristol-Myers Squibb Company (BMY): One of the Best Performing Dividend Stocks to Buy Now - Insider Monkey
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
J&J, Protagonist's oral psoriasis prospect bests BMS' Sotyktu in pair of phase 3 trials - Fierce Biotech
Bristol-Myers Squibb (NYSE:BMY) Hits New 52-Week High – Here’s What Happened - Defense World
Is Bristol-Myers Squibb Company (BMY) The Best Cheap Dividend Stock To Buy Right Now? - Insider Monkey
Bristol-Myers Squibb Co (BMY) Announces Positive Phase 3 Trial Results for Sotyktu in Psoriatic Arthritis - GuruFocus.com
Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis - Lelezard
BMYBristol-Myers Squibb Co Latest Stock News & Market Updates - StockTitan
Jim Cramer Highlights ‘Multi-Billionaire Dollar’ Catalyst for Bristol-Myers Squibb. Co (BMY) - MSN
Market Whales and Their Recent Bets on BMY Options - Benzinga
Zollinger Ellison Syndrome Market Research 2025: Novartis, GSK Plc, Bayer, Pfizer., and Bristol Myers Squibb Leading the $1.34 Billion LandscapeForecasts to 2034 - GlobeNewswire
Cell And Gene Therapy For Multiple Myeloma Market Forecasted - openPR
Jim Cramer Highlights ‘Multi-Billionaire Dollar’ Catalyst for Bristol-Myers Squibb Company (BMY) - Insider Monkey
BMY Stock Price and Chart — NYSE:BMY - TradingView
BMY stock touches 52-week high at $61.11 amid market rally - Investing.com
Bristol Myers' Opdivo Plus Yervoy Combo Therapy Secures European Approval For Untreated Liver Cancer Patients - Benzinga
(ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma - Business Wire
Layoff Tracker: Atea Pharmaceuticals Cuts 25% of Workforce - BioSpace
How Is The Market Feeling About Bristol-Myers Squibb? - Benzinga
Why a Big Pharma player is shutting down a Bay Area site, consolidating at anotherSan Francisco Business Times - The Business Journals
UPDATE: Bristol Myers' cost-savings drive claims another 280 jobs in US - FiercePharma
13 Best Cheap Dividend Stocks To Buy Right Now - Insider Monkey
Cell Therapy Market to Witness Remarkable Growth with Bristol Myers Squibb Company, Amgen Inc - openPR
Bristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending Cardiomyopathy Research Deal - Benzinga
Cell Therapy Market Projected To Witness Substantial Growth, 2025-2032: Bristol Myers Squibb Company, Novartis - EIN News
Is Bristol-Myers Squibb Company (BMY) the Best Dividend Stock to Buy According to Billionaires? - Insider Monkey
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.55%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):